M281, an anti‐FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first‐in‐human study

LE Ling, JL Hillson, RG Tiessen, T Bosje… - Clinical …, 2019 - Wiley Online Library
M281 is a fully human, anti‐neonatal Fc receptor (FcRn) antibody that inhibits FcRn‐
mediated immunoglobulin G (IgG) recycling to decrease pathogenic IgG while preserving …
被引用次数：123 相关文章

M281, an Anti‐FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First‐in‐Human Study

LE Ling, JL Hillson, RG Tiessen, T Bosje… - Clinical Pharmacology …, 2018 - cir.nii.ac.jp
抄録< jats: p> M281 is a fully human, anti‐neonatal Fc receptor (FcRn) antibody that inhibits
FcRn‐mediated immunoglobulin G (IgG) recycling to decrease pathogenic IgG while …

M281, an Anti‐FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First‐in‐Human Study.

LE Ling, JL Hillson, RG Tiessen… - Clinical …, 2019 - search.ebscohost.com
M281 is a fully human, anti‐neonatal Fc receptor (FcRn) antibody that inhibits FcRn‐
mediated immunoglobulin G (IgG) recycling to decrease pathogenic IgG while preserving …

M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study.

LE Ling, JL Hillson, RG Tiessen, T Bosje… - Clinical …, 2018 - europepmc.org
M281 is a fully human, anti‐neonatal Fc receptor (FcRn) antibody that inhibits FcRn‐
mediated immunoglobulin G (IgG) recycling to decrease pathogenic IgG while preserving …
[HTML] nih.gov

[HTML][HTML] M281, an Anti‐FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First‐in‐Human Study

LE Ling, JL Hillson, RG Tiessen, T Bosje… - Clinical …, 2019 - ncbi.nlm.nih.gov
M281 is a fully human, anti‐neonatal Fc receptor (FcRn) antibody that inhibits FcRn‐
mediated immunoglobulin G (IgG) recycling to decrease pathogenic IgG while preserving …

M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study

LE Ling, JL Hillson, RG Tiessen, T Bosje, MP van Iersel… - 2019 - pubmed.ncbi.nlm.nih.gov
M281 is a fully human, anti-neonatal Fc receptor (FcRn) antibody that inhibits FcRn-
mediated immunoglobulin G (IgG) recycling to decrease pathogenic IgG while preserving …
[PDF] academia.edu

[PDF][PDF] M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study

LE Ling, JL Hillson, RG Tiessen, T Bosje… - CLINICAL …, 2019 - academia.edu
M281 is a fully human, anti-neonatal Fc receptor (FcRn) antibody that inhibits FcRn-
mediated immunoglobulin G (IgG) recycling to decrease pathogenic IgG while preserving …
[PDF] losinglucyandfindinghope.com

[PDF][PDF] M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study

LE Ling, JL Hillson, RG Tiessen… - CLINICAL …, 2019 - losinglucyandfindinghope.com
M281 is a fully human, anti-neonatal Fc receptor (FcRn) antibody that inhibits FcRn-
mediated immunoglobulin G (IgG) recycling to decrease pathogenic IgG while preserving …

M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study.

LE Ling, JL Hillson, RG Tiessen, T Bosje… - Clinical …, 2018 - europepmc.org
M281 is a fully human, anti‐neonatal Fc receptor (FcRn) antibody that inhibits FcRn‐
mediated immunoglobulin G (IgG) recycling to decrease pathogenic IgG while preserving …